Announcements Trials

Browse Landscape

Phase

Phase NA 12 Phase 2 11 Phase 3 2 Phase 4 1 Phase 2/3 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lung Neoplasms 3 Neoplasms 2 Esophageal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Suspected Central Nervous System Tumors 1 Stomach Neoplasms 1 Solitary Pulmonary Nodule 1 Rectal Neoplasms 1 Multiple Pulmonary Nodules 1 Lymphedema 1 Head and Neck Neoplasms 1 Head and Neck Carcinoma 1 Giant Cell Tumor of Bone 1 Colorectal Neoplasms 1 Chylothorax 1 Breast Neoplasms 1

Interventions

Trastuzumab 62 Paclitaxel 57 Cyclophosphamide 44 pembrolizumab 34 Fulvestrant 34 Capecitabine 29 Carboplatin 26 Docetaxel 23 Letrozole 22 Doxorubicin 19 palbociclib 16 abemaciclib 16 pertuzumab 15 durvalumab 14 Filgrastim 13 Everolimus 13 ribociclib 12 Lapatinib 12 Gemcitabine 12 exemestane 11 eribulin 11 Vinorelbine 11 Albumin-Bound Paclitaxel 11 Bevacizumab 10 trastuzumab deruxtecan 9 neratinib 9 fludarabine 9 Taxes 9 Radiotherapy 9 Peripheral Blood Stem Cell Transplantation 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Breast Neoplasms × Indocyanine Green × Clear all

NCT01993576 2014-10-15

EC2075

Jules Bordet Institute

Phase 1/2 Completed

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡